<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483717</url>
  </required_header>
  <id_info>
    <org_study_id>ROX-2007-01</org_study_id>
    <nct_id>NCT00483717</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egalet Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egalet Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute
      treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment
      of migraine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point.</measure>
    <time_frame>2 hours after dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>0.5 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>1 hour post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>1.5 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>3 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>4 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>24 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</measure>
    <time_frame>48 hours post-dosing</time_frame>
    <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intranasal Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal ketorolac tromethamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine</intervention_name>
    <description>31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal (IN) placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of migraine with or without aura (IHS criteria 1.1 and 1.2.1);

          -  Onset of migraine prior to age 50;

          -  2-8 moderate to severe migraine headaches per month

        Exclusion Criteria:

          -  Subjects receiving any investigational drug within 30 days before study entry;

          -  More than 15 headache days per month;

          -  Known allergy or hypersensitivity to ketorolac and/or excipients;

          -  Allergy to aspirin or other NSAIDs;

          -  Currently receiving other NSAIDs or aspirin;

          -  Medical history that would preclude NSAID use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Whiting, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Luitpold Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Volker Pfaffenrath</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <results_first_submitted>August 31, 2012</results_first_submitted>
  <results_first_submitted_qc>September 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Ketorolac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 months and 3 weeks; Medical Centers and Hospitals</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac Tromethamine</title>
          <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time of dosing missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No treatment for migraine</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac Tromethamine</title>
          <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="173"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="11.4"/>
                    <measurement group_id="B2" value="38.5" spread="11.6"/>
                    <measurement group_id="B3" value="38.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point.</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>2 hours after dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point.</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>0.5 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>1 hour post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>1.5 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>3 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>4 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>24 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
        <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
        <time_frame>48 hours post-dosing</time_frame>
        <population>Modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine</title>
            <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Treated Subjects Who Became Pain-free (IHS Grade 0) by Observation Time Point</title>
          <description>Pain was evaluated using a 4-point International Headache Society (IHS) scale where grade 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain</description>
          <population>Modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months and 3 weeks</time_frame>
      <desc>ITT population</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac Tromethamine</title>
          <description>Intranasal ketorolac tromethamine
Ketorolac tromethamine : 31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intranasal Placebo
Placebo : Intranasal (IN) placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intranasal hypoaesthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pharyngeal hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Bregman, M.D., Ph.D</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>601-650-4200 ext 828</phone>
      <email>dbregman@lpicrd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

